We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cambridge Cognition Holdings Plc | LSE:COG | London | Ordinary Share | GB00B8DV9647 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 48.00 | 47.00 | 49.00 | 48.00 | 48.00 | 48.00 | 19,972 | 07:31:25 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 12.61M | -409k | -0.0117 | -41.03 | 16.73M |
TIDMCOG
RNS Number : 7369P
Cambridge Cognition Holdings PLC
31 May 2018
Cambridge Cognition Holdings Plc
('Cambridge Cognition' or the 'Company')
New client signs with Cognition Kit software
The digital neuroscience company Cambridge Cognition Holdings plc, (AIM: COG, 'the Company'), which develops and markets digital solutions to assess brain health, has announced a new $0.5m contract with a major pharmaceutical company for the use of its Cognition Kit(TM) digital health software in a clinical trial.
Cognition Kit measures cognitive health on mobile and wearable devices, enabling researchers to gather data in everyday life and clinicians to make more insightful treatment decisions for their patients.
This clinical trial will monitor patients diagnosed with a neurological condition for 12 months. During this time, participants will use a Cognition Kit smartphone app to test their brain health remotely and frequently, providing the sponsor with rich real-world data outside of clinical sites in a more holistic, cost-effective and patient-centric fashion.
The new contract follows the Company's successful collaborations with existing Cognition Kit partners and further negotiations with other major pharmaceutical companies are at an advanced stage.
Dr Steven Powell, Chief Executive Officer, at Cambridge Cognition said: "The pharmaceutical industry is increasingly looking to develop novel biomarkers and use digital phenotyping techniques to improve their data intelligence and market access. Having successfully demonstrated the effectiveness of Cognition Kit technology through our ongoing partnership with Takeda, we are delighted to be signing additional clients with whom we expect to establish long-lasting commercial partnerships."
Enquiries
Cambridge Cognition Holdings PLC Steven Powell, Chief Executive Tel: 01223 810 Officer 700 Noah Konig, Director of Marketing press@camcog.com finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 Geoff Nash / Simon Hicks 0500 Alice Lane (Corporate Finance) (Corporate Broking) Dowgate Capital Stockbrokers Limited Tel: 020 3903 (Joint Broker) 7715 David Poutney / James Serjeant IFC Advisory Ltd (Financial PR Tel: 020 3934 and IR) 6630 Graham Herring / Miles Nolan / Zach Cohen
About Cognition Kit Limited
Cognition Kit is a joint venture between Cambridge Cognition and Ctrl Group formed to develop scientifically valid digital health apps on mobile and wearable devices. Cognition Kit software takes research out of the lab and into everyday life, enabling doctors, scientists and the public to better understand and manage brain health.
For further information visit www.cognitionkit.com
About Cambridge Cognition Holdings PLC
Cambridge Cognition is a digital neuroscience company developing software products to better understand, detect and treat brain health conditions. The company's cognitive technologies are used to accelerate the research and development of new treatments, enhance understanding of the brain and accurately assess cognitive health in patients worldwide.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
CNTSDSFISFASEDI
(END) Dow Jones Newswires
May 31, 2018 02:00 ET (06:00 GMT)
1 Year Cambridge Cognition Chart |
1 Month Cambridge Cognition Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions